Prefilled Syringe Market
The future of the global prefilled syringe market looks promising with opportunities in the hospital/clinic and ambulatory surgical center markets. The global prefilled syringe market is expected to reach an estimated $12.3 million by 2035 from $8.5 million in 2027 with a CAGR of 4.7% from 2027 to 2035. The major drivers for this market are the growing demand for ready-to-use injectable products, the increasing vaccination programs & injectable therapies demand, and the rising preference for home-based treatment.
- Lucintel forecasts that, within the product type category, safety is expected to witness higher growth over the forecast period due to the need for enhanced patient safety and reduced needle injuries.
- Within the application category, hospitals/clinics is expected to witness the highest growth over the forecast period due to the rising hospital based vaccination and treatment administration demand.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding healthcare infrastructure and large patient population growth.
Emerging Trends in Prefilled Syringe Market
The prefilled syringe market is expected to change from a packaging format to an integrated drug delivery format during the 2025 to 2027 time frame. Lucintel reports biologics and home care are driver changes with respect to supplier prioritization. Also, regulatory and manufacturing factors impact supplier decisions. Lucintel reports a growing trend toward ready-to-use systems based on the injectable drug pipeline and the increased focus on reducing preparation errors at hospitals.
- Sustainability: In 2025, multiple suppliers expanded their offerings with lower-material designs and programs with recyclable components; this, along with efforts to reduce weight in glass and cyclic olefin polymer packaging, began to influence what suppliers offer; this trend will affect purchasing as pharmaceutical companies start to measure the lifecycle emissions of their supply chains.
- Automation: Vision inspection and robotic assembly with high-speed filling lines able to operate at 600 units per minute began to be deployed in pharmaceutical production facilities in 2025; the focus on automation to improve consistency and affordability will likely drive growth in the market.
- Biologics Compatibility: In 2025, polymeric and low-silicone systems, as well as advanced methods for the control of tungsten and other heavy metals, gained adoption for the delivery of biologics and gene therapies; due to the nature of these sensitive molecules, control of particulates and container interactions become even more critical.
- Self-administration: In 2025, the focus was on the delivery of biologic medicines for home use, and the use of prefilled syringes and autoinjectors to improve adherence; the U.S. accounted for approximately 40% of global biologic medicine spending in 2025.
- Supply Chain Diversification: The shortages have demonstrated the drugmakers' over-reliance on single-source suppliers for active components, as well as dependence on a few manufacturing regions. As a result, drugmakers are qualifying second-source suppliers. Simultaneously, they are developing regional supply capacities. In the coming five years, the contracts will favor suppliers that have the capacity to ensure continuity of supply, and quality of supply, along with shorter replenishment cycles.
The suppliers that integrate container and device engineering will gain in this market. The strongest growth will occur with injectable therapies moving to outpatient settings. Developing devices to deliver therapeutics that meet regional requirements will increase the cost of doing business, but it will create an opportunity for favored suppliers. Traditionally, drug development is standardized and product differentiation relies on equipment and components.
Recent Developments in the Prefilled Syringe Market
The pace of activity in the prefilled syringe market is increasing for the years 2025-2027 as requirements for biologics and GLP-1 therapies change the delivery scene. Self-injection is also gaining ground. Per Lucintel, competition is also shifting to high-volume manufacturing, complexity in drug compatibility, and integrated device systems. Pharmaceutical companies are looking for reliable, scalable fill-finish partners, and manufacturers are making investments in anticipation of future demand.
- Partnerships: In February 2025, Gerresheimer and Corning extended their partnership on Valor Glass for pharmaceutical packaging. Stronger glass systems address breakage, contamination, and regulatory concerns for injectable medicines.
- Launches: In March 2025, SHL Medical announced a new set of platform developments for connected auto injectors and PSF-based systems. Other advances include an improved understanding of the patient experience, real time data exchange, and a greater focus on adherence.
- Localization: In 2025, a number of primary suppliers expanded their fill-finish and syringe capacity in the U.S., in order to address demand for domestic manufacturing. Until now, local supply has taken a backseat to lowest cost; however there have been restrictions on trade, supply chain disruptions, and concentrated buying by governments.
- GLP-1: In January 2025, Novo Nordisk announced 2024 revenue of DKK 290.4B, primarily from the sale of GLP-1 medicines. High demand for GLP-1 will lead to an increased need for high-volume prefilled syringes. Additionally, increased demand will strain supply and further stress component costs.
The injection industry is moving away from a standard container supply, toward more integrated delivery ecosystems. Suppliers with validated container and closure components, along with automation and flexible capacity, are well-positioned for prime contracts. Contract visibility is limited due to changing drug approvals and reformulations. Through 2027, sustained growth will be driven by biologics, home treatment and the manufacturing resilience becoming a key purchasing factor.
Strategic Growth Opportunities in the Prefilled Syringe Market
The prefilled syringe market is set to flourish with the ongoing market trends like biologics, self-administration and increasing need for medication safety between 2024 and 2026. From a medical device perspective, Lucintel expects that the demand will shift towards higher value, more integrated and advanced delivery systems and away from simple container volume.
- Biologics-compatible Systems: With low-interaction materials, increasing numbers of biologics will gain FDA-listing; for ex. in Feb 2025, the total number was over 700. The opportunity will create the need for delivery systems that offer dependable long-term stability, lower the levels of extractable, and have performance assurances throughout the storage and use of the product.
- Home-care Delivery: Easier-to-use prefilled syringe formats will be available for patients that receive their therapies outside hospitals. The World Health Organization (WHO) reported in January 2025 that non-communicable diseases resulted in over 41 million deaths per year. This will increase the demand for recurring self-administered treatments. In the next 3-5 years, home care will transform purchasing to more ergonomic and safer devices.
- Specialty Injectable Applications: Specialty syringe programs in oncology and immunology and in the treatment of rare diseases with advanced needle systems and coatings will continue to expand. In March 2025, the U.S. Food and Drug Administration (FDA) approved more than 40 biosimilars. The demand for specialty drugs will raise the value of individual units sold and benefit component suppliers.
- Regionalized Manufacturing: Pharmaceutical companies will bring more production and filling capabilities to the areas where they source their raw materials and suppliers. In April 2025, the European Commission (EC) stated that more than 260 pharmaceutical products were at risk for supply disruption. Government and hospital focus on continuity of supply will drive procurement toward regional production.
- Prefilled syringes offer several opportunities, including dosage tracking and personalization for patients. In May 2025, the FDA approved more than 20 combination products during the year-to-date period. Integration of devices and drugs will challenge the industry to further improve product designs, software, and validate aftermarket services. The biopharmaceutical industry will focus on treatment outcomes.
We expect the strongest growth in prefilled syringes will come from suppliers integrating the design and validation of drug delivery devices with lifecycle support. This will be concentrated in regions supplying biopharmaceuticals. Competitive forces will drive biopharmaceutical suppliers to partner with lifecycle product support firms, as well. Adherence to self-administration will maintain healthy demand for prefilled syringes and other devices for drug delivery beyond the hospital setting for the next five years.
Prefilled Syringe Market Drivers and Challenges
The expansion of the prefilled syringe market is mostly due to the advancement of technology, economic situations, and government regulations. Expanding requirements to administer biologics, manufacture using automation, and integrate sustainability initiatives in the pharmaceutical industry present growth opportunities. Challenges are best described by competing needs, such as the increased demand for safety and automation versus the need for more supply flexibility and cost effectiveness. Lucintel predicts that in order to be successful, companies must build reliable production, user-friendly design, and flexible innovations.
The factors responsible for driving this market include:
- Biologics Expansion: Increasing demand for biologics, vaccines, and other injectable therapies drives the need for more convenient and precise dosage delivery systems. Thousands of biologics candidates in the global pharmaceutical pipeline (as of January 2025) support the growing use of injectable treatments. In the next 3 to 5 years, with an increase in biologics approvals and the treatments for chronic conditions, the market will require prefilled syringes to reduce the risk of preparation and administration errors.
- Self-administration: With patients preferring home-based treatments for conditions like diabetes and other chronic autoimmune conditions, manufacturers are developing syringes to make drug administration easier. In 2025, injectable therapies were the major component of specialty drug treatments in several established healthcare systems. In the next 3 to 5 years, the market will require syringes that are easy to use and have features like integrated needles and safety.
- Technology Advancements: New polymer materials and integrated sensor and motor technologies increase safety and performance of syringes and other connected devices. In 2025, high-precision vision systems to perform in-line inspection of syringes at high speed (600+ units/min) became common in manufacturing. In the next 3 to 5 years, digital quality and controls, and smart delivery will foster further differentiation and packaging security in the pharmaceutical industry.
- Regulatory Support: Emphasis by regulatory authorities on medication safety, serialization of drugs and doses, combination products, and standardized drug delivery systems has motivated the shift to the use of prefilled syringes in the pharmaceutical industry. In April 2025, regulators strengthened their expectations around container-closure integrity and usability of devices. This provides opportunities for suppliers who can validate their materials and build robust documentation to support human-factor testing and manufacturing systems to meet challenging regulatory requirements.
- Manufacturing: Continuous improvement in automation in manufacturing has led to reductions in labor dependence, increase in speed, and improved consistency. In May 2025, multiple advanced filling lines achieved an output of more than 400 prefilled syringes per minute, dependent on the product filled. Within the next three to five years, ongoing improvements will help manufacturers fulfill rising customer demands for greater contract manufacturing of injectable drugs and biologics, minimize unit costs, and reduce waste.
The challenges facing this market include:
- High Production Costs: The specialized materials and processes needed for the production of prefilled syringes lead to greater costs compared to vials and syringes. In June 2025, several injectable drug manufacturers cited packaging material and quality control as significant cost drivers, particularly for small batches of biologics. Challenges will motivate the substitution of materials, automate processes and improve manufacturing systems and suppliers to achieve greater cost reduction without impacting the integrity and stability of the drug.
- Supply Chain Vulnerability: Pharmaceutical companies rely on a handful of companies for raw materials (pharmaceutical-grade glass, elastomers, specialty polymers, needles, and contract sterilization services). Manufacturers face shortages and supply-chain disruption risks. Many healthcare supply chains maintained a safety inventory of several weeks of critical components for injectables in July 2025. Between 2025 and 2030, pharmaceutical companies will need to maintain regional supplies, use dual suppliers, maintain strategic inventories, and utilize flexible production to avoid delays in the launch of pharmaceutical products.
- Regulatory and Technical Complexity: The development of drug delivery systems is technically challenging and cost-prohibitive. In 2025, the combination product evaluations almost always required multiple performance and human factors datasets prior to being allowed for commercial use. The combination of the technical challenges with the regulatory complexity will increase development times and costs, and cause a reliance on a few suppliers that can effectively integrate all required elements of pharmaceutical and medical device development.
The factors that are promoting the use of prefilled syringes for the delivery of biologics are also encouraging the automation of self-administration and the development of delivery systems for other routes of administration. The replacement of vials and the related systems by prefilled syringes is being adopted by pharma companies. However, there are multiple constraints such as the supply-chain challenges, high cost of goods and delivery systems, material specialization, and an inadequate supplier base, and complexity of the regulatory environment that will challenge the growth of this market. Participants in this space that can improve supply-chain and production automation, while considering sustainability and enhancing usability of devices will have a competitive edge. Overall, there will be significant demand for user-friendly devices that are safe, affordable, and produced in adequate supply.
List of Prefilled Syringe Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies prefilled syringe market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prefilled syringe market companies profiled in this report include-
- Becton, Dickinson, and Company
- Gerresheimer AG
- B. Braun Melsungen
- Schott AG
- Baxter International
Prefilled Syringe Market by Segment
The study includes a forecast for the global prefilled syringe market by product type, material, application, end use, and region.
Prefilled Syringe Market by Product Type [Value ($M) from 2019 to 2035]:
Prefilled Syringe Market by Material [Value ($M) from 2019 to 2035]:
- Glass-Based
- Plastic-Based
Prefilled Syringe Market by Application [Value ($M) from 2019 to 2035]:
- Anaphylaxis
- Diabetes
- Rheumatoid Arthritis
- Others
Prefilled Syringe Market by End Use [Value ($M) from 2019 to 2035]:
- Hospitals/Clinics
- Ambulatory Surgical Centers
- Others
Prefilled Syringe Market by Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Prefilled Syringe Market
The prefilled syringe market has experienced significant growth driven by increasing demand for safe, convenient, and efficient medication delivery systems worldwide. Technological innovations, regulatory approvals, and expanding healthcare infrastructure have contributed to market expansion. Countries are focusing on product development, regulatory compliance, and market penetration to meet rising healthcare needs. The evolving landscape reflects a shift towards more patient-friendly and sterile injection options, especially in response to the COVID-19 pandemic and the growing prevalence of chronic diseases. This dynamic environment presents opportunities for manufacturers to innovate and expand their market share across different regions.
- United States: The US market for prefilled syringes is witnessing rapid growth due to rising adoption of biologics and vaccines. Key advancements include the development of auto-injectors and safety syringes to enhance patient safety. Regulatory agencies like the FDA are streamlining approval processes, encouraging innovation. The increasing prevalence of chronic diseases and the COVID-19 vaccination campaigns have further boosted demand. Major players are investing in R&D to develop advanced, customizable prefilled syringes with improved stability and safety features. The US remains a leading market with a focus on technological innovation and regulatory compliance.
- China: China's prefilled syringe market is expanding swiftly, driven by a large population base and increasing healthcare infrastructure investments. The government's focus on vaccine development and immunization programs has accelerated market growth. Local manufacturers are adopting advanced manufacturing techniques to improve product quality and reduce costs. The rising prevalence of chronic diseases and the COVID-19 pandemic have increased demand for injectable drugs. Regulatory reforms are facilitating faster approvals and market entry for new products. China is also witnessing a surge in domestic innovation, with companies developing smart syringes and environmentally friendly options to meet global standards.
- Germany: Germany's market is characterized by high-quality standards and technological innovation. The country is a key hub for medical device manufacturing within Europe, with a focus on safety and precision. Recent developments include the integration of digital technologies into prefilled syringes, such as smart syringes with electronic tracking. The increasing use of biologics and personalized medicine has driven demand for specialized prefilled syringes. Regulatory frameworks are strict, ensuring product safety and efficacy. German companies are investing in sustainable manufacturing practices and advanced materials to enhance product performance. The market continues to grow steadily, supported by robust healthcare infrastructure.
- India: The Indian prefilled syringe market is experiencing rapid growth due to rising healthcare awareness and increasing government initiatives to improve healthcare access. The expanding pharmaceutical sector and the growing prevalence of chronic diseases are key drivers. Local manufacturers are focusing on cost-effective, high-quality products to cater to both domestic and export markets. The COVID-19 pandemic has further accelerated demand for prefilled syringes, especially for vaccines and injectable drugs. Regulatory agencies are streamlining approval processes to facilitate market entry. Innovations in packaging and materials are also emerging, aiming to improve safety and usability in rural and urban settings.
- Japan: Japan's market for prefilled syringes is driven by an aging population and the increasing prevalence of chronic conditions requiring injectable treatments. The focus is on developing advanced, user-friendly, and safe syringe options. Recent developments include the integration of safety features and ergonomic designs to reduce needlestick injuries. Japanese companies are investing in biocompatible materials and environmentally sustainable manufacturing processes. The government's emphasis on healthcare innovation and regulatory support has fostered a conducive environment for new product launches. The market is characterized by high standards for quality and safety, with steady growth aligned with technological advancements and demographic needs.
Features of the Global Prefilled Syringe Market
- Market Size Estimates: prefilled syringe market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: prefilled syringe market size by various segments, such as by product type, material, application, end use, and region in terms of value ($M).
- Regional Analysis: prefilled syringe market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product type, material, application, end use, and regions for the prefilled syringe market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prefilled syringe market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the prefilled syringe market by product type (conventional and safety), material (glass-based and plastic-based), application (anaphylaxis, diabetes, rheumatoid arthritis, and others), end use (hospitals/clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?